A new treatment for severe nausea and vomiting during pregnancy
Official title: Therapeutic antibody for hyperemesis gravidarum
Funded at Larix Bioscience, LLC · NIH-10601709 · Data updated 2026-11-12
This study is working on a new treatment for hyperemesis gravidarum, a tough condition that causes severe nausea and vomiting during pregnancy, by creating an antibody that targets a specific protein linked to the condition, aiming to help women feel better.
Quick facts
| Grant type | Sbir 1 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Larix Bioscience, LLC NIH-funded |
| Lab location | 1 site (Sunnyvale, United States) |
| Project start | September 19, 2022 |
| Project end | August 31, 2025 |
| Funding year | 2022 |
| Award (this year) | $300,847 |
| NIH project number | 1R43HD107741-01A1 |
| Project ID | NIH-10601709 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are pregnant women who are experiencing hyperemesis gravidarum.
✕Less likely to help
Patients who are not pregnant or those with mild nausea and vomiting not classified as hyperemesis gravidarum may not benefit from this research.
What this research studies
This research focuses on developing a therapeutic antibody to treat hyperemesis gravidarum (HG), a severe condition characterized by extreme nausea and vomiting in pregnant women. The study investigates the role of a protein called GDF15, which is linked to HG, and aims to create a monoclonal antibody that can neutralize its effects. By analyzing genetic factors and conducting preclinical trials, the research seeks to provide a more effective treatment option for women suffering from this debilitating condition.
Why it matters
Potential benefit: If successful, this research could provide a much-needed effective treatment for women experiencing severe nausea and vomiting during pregnancy.
How similar studies have gone: Previous research has shown success in using monoclonal antibodies to target similar pathways in other conditions, suggesting potential for this approach in treating hyperemesis gravidarum.
Where this research is happening
-
Larix Bioscience, LLC
Sunnyvale, United States Active
Researchers
- Principal investigator: Mendelsohn, Andrew R — Larix Bioscience, LLC
- Study coordinator: Mendelsohn, Andrew R
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.